To examine whether defective muscle glycogen synthase (GYS1) expression is associated with impaired glycogen synthesis in type 2 diabetes and whether the defect is inherited or acquired, we measured GYS1 gene expression and enzyme activity in muscle biopsies taken before and after an insulin clamp in 12 monozygotic twin pairs discordant for type 2 diabetes and in 12 matched control subjects. The effect of insulin on GYS1 fractional activity, when expressed as the increment over the basal values, was significantly impaired in diabetic (15.7 Ϯ 3.3%; P Ͻ 0.01), but not in nondiabetic (23.7 Ϯ 1.8%; P ϭ NS) twins compared with that in control subjects (28.1 Ϯ 2.3%). Insulin increased GYS1 messenger ribonucleic acid (mRNA) expression in control subjects (from 0.14 Ϯ 0.02 to 1.74 Ϯ 0.10 relative units; P Ͻ 0.01) and in nondiabetic (from 0.24 Ϯ 0.05 to 1.81 Ϯ 0.16 relative units; P Ͻ 0.01) and diabetic (from 0.20 Ϯ 0.07 to 1.08 Ϯ 0.14 relative units; P Ͻ 0.01) twins. The effect of insulin on GYS1 expression was, however, significantly reduced in the diabetic (P Ͻ 0.003), but not in the nondiabetic, twins compared with that in control subjects. The postclamp GYS1 mRNA levels correlated strongly with the hemoglobin A 1c levels (r ϭ Ϫ0.61; P Ͻ 0.001). Despite the decrease in postclamp GYS1 mRNA levels, the GYS1 protein levels were not decreased in the diabetic twins compared with those in the control subjects (2.10 Ϯ 0.46 vs. 2.10 Ϯ 0.34 relative units; P ϭ NS). We conclude that 1) insulin stimulates GYS1 mRNA expression; and 2) impaired stimulation of GYS1 gene expression by insulin in patients with type 2 diabetes is acquired and most likely is secondary to chronic hyperglycemia. (J Clin Endocrinol Metab 85: 1584 -1590, 2000 
I
MPAIRMENT of glucose metabolism in skeletal muscle is a characteristic feature of patients with type 2 diabetes and is mostly accounted for by impaired glycogen synthesis (1, 2) . The finding of impaired insulin-stimulated glycogen synthesis in first degree relatives of patients with type 2 diabetes (3-5) points at an inherited defect and the possibility that variations in the skeletal muscle glycogen synthase (GYS1) gene could be involved. However, apart from a relatively common polymorphism (6) , only rare alterations in the coding region of the GYS1 gene have been found in patients with type 2 diabetes (7). Thus, a defect in the transcription or translation of the gene could also be involved. In support of this view, decreased expression of the glycogen synthase gene was reported in cultured skeletal muscle cells (8) and in muscle biopsies from patients with type 2 diabetes (9, 10).
The exact mechanism behind impaired glycogen synthase gene expression in skeletal muscle of type 2 diabetes is not known, particularly because there is little, if any, information available on the regulation of GYS1 gene expression by insulin. In addition to a genetic component, it has been proposed that hyperglycemia per se can contribute to impaired glycogen synthesis in patients with type 2 diabetes. In keeping with this hypothesis, chronic exposure of cultured human skeletal muscle cells from normal subjects to high insulin and/or glucose resulted in impaired glycogen synthase activity (11) . The relative contributions of inherited and acquired defects to impaired skeletal muscle glycogen synthase activity are difficult to study in vivo in humans, as it would require study of the effect of hyperglycemia on an identical genetic background. We have taken advantage of our unique access to monozygotic twins by examining GYS1 gene expression and enzyme activity in muscle biopsies taken before and after an insulin clamp from 12 monozygotic twin pairs discordant for type 2 diabetes and from 12 control subjects (12, 13) . Glycogen synthase protein concentrations were also measured in skeletal muscle from diabetic and nondiabetic subjects.
Subjects and Methods Subjects
Twelve Caucasian monozygotic twin pairs discordant for type 2 diabetes and 12 healthy subjects without family history of diabetes participated in the study. Type 2 diabetes had been diagnosed after the age of 40 yr based upon a standardized 75-g oral glucose tolerance test (14) . The control subjects were matched to the nondiabetic twins for age, sex, and body mass index (Table 1) . Monozygosity of the twins was confirmed by genetic markers (13) . Insulin sensitivity was measured by a 3-h euglycemic hyperinsulinemic clamp with prior infusion of insulin (15) . Muscle biopsies were obtained in the basal state (0 min) approximately 150 min after the prior insulin infusion was stopped and at the end of the clamp (ϩ180 min); samples were frozen immediately in liquid nitrogen and stored at Ϫ80 C until analyzed. Informed consent was obtained from all subjects. The protocol was approved by the regional ethics committee, and the study was conducted according to the principles of the Declaration of Helsinki. Insulin clamp data in the twins have been published previously (13) .
Glycogen synthase activity
Extraction of muscle samples and assays for glycogen synthase were performed using a modified method of Thomas et al. (5) . Briefly, glycogen synthase activity was measured in the presence of a near-physiological concentration of 0.1 mmol/L glucose-6-phosphate and in the presence of a high concentration of 10 mmol/L glucose-6-phosphate. The total concentration of uridine diphosphate glucose ([ 14 C]UDPG and cold UDPG) was 0.31 mmol/L in the reaction. Fractional velocities were calculated as the ratio between glycogen synthase activities at 0.1 mmol/L glucose-6-phosphate and 10 mmol/L glucose-6-phosphate (FV 0.1). Total glycogen synthase activities were estimated as the activities at a glucose-6-phosphate concentration of 10 mmol/L and a total UDPG concentration of 5 mmol/L. Glycogen synthase activity was expressed as nanomoles of UDPG incorporated into glycogen per min/mg extract of protein. Data for GYS1 enzyme activity in the twins have been published previously (12) .
Glycogen synthase messenger ribonucleic acid (mRNA)
The RNA expression of glycogen synthase was examined using a modified "primer-dropping" RT-PCR method (16) . Total RNA was isolated from the muscle biopsies by the acid guanidinium thiocyanate method (17) . Four hundred nanograms of total RNA from each sample were then reverse transcribed in a 40-L reaction with a 5 mol/L oligo(deoxythymidine) 18 primer in the presence of 200 U Superscript II reverse transcriptase (Life Technologies, Inc., Glasgow, Scotland) and 25 mol/L deoxy-NTP for 60 min at 37 C according to the manufacturer's instruction. After heat inactivation of the reverse transcriptase at 95 C for 5 min, 2 L of the RT reaction were added to 18 L PCR mixture containing 16 mmol/L (NH 4 ) 2 SO 4 , 67 mmol/L Tris base, 0.01% Tween-20, 0.2 mmol/L deoxy-NTP, 1.5 mmol/L MgCl 2 , 7.5% dimethylsulfoxide, 0.5 U Taq polymerase, 0.2 mol/L primers for the GYS1 gene (GSF and GSR), and 0.6 mol/L primers for the cyclophilin gene (cycloF and cycloR) as the reference. The GYS1 primer pairs (from 5Ј to 3Ј) were TTCTGGACTGGAAATAC-CTAGGCCGG (GSF) and CTCTGCATCCTCTCTCTGGAGCAGAG (GSR). The cyclophilin primer pairs were GTCTCCTTTGAGCTGTT-TGC (cycloF) and TGGCCTCCACAATATTCATGC (cycloR). To avoid genomic DNA amplification, the glycogen synthase primers define a region spanning introns 14 and 15 of the GYS1 gene (18) , whereas cyclophilin primers define the intron-exon borders of the gene structure (GenBank accession no. X52851). The PCR was run for 40 cycles (96 C, 30 s; 62 C, 30 s; 72 C, 30 s) and was followed by a final extension at 72 C for 10 min. The PCR condition was optimized according to the primer-dropping method (16) to maintain coamplification within the exponential phase. Selection of the cyclophilin gene as a reference was based upon its unaffected expression in the insulin-resistant and diabetic state (19) . Validation of this method has been described in a previous study (20) . PCR products were separated on a 2% agarose gel containing ethidium bromide, photographed with UPP-110HA printing paper (Sony, Tokyo, Japan), and quantitated using Personal Densitometer SI scanner together with ImageQuant software (Molecular Dynamics, Sunnyvale, CA). The mRNA signals were expressed relative to that of cyclophilin.
Glycogen synthase protein
The glycogen synthase protein was measured in muscle biopsies taken from the twins with type 2 diabetes and control subjects after the insulin clamp. Muscle samples were homogenized in 20 mmol/L HEPES, 1 mmol/L ethylenediamine tetraacetate, and 250 mmol/L sucrose, pH 7.4. Total protein levels in muscle extract were measured using the Pierce Chemical Co. bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, IL) according to the manufacturer's instruction. Equal amounts of total protein (20 g) from each sample were run in SDS-PAGE, transferred to nitrocellulose membranes, and blotted against an antibody raised in rabbit against a COOH-terminal 12-amino acid oligopeptide of human muscle glycogen synthase, as previously described (6) . The blots was then incubated with a horseradish peroxidaseconjugated antirabbit IgG (Sigma, St. Louis, MO), and the signal was detected with the ECL Western Blot Detection Kit (Amersham Pharmacia Biotech, Aylesbury, UK). The amount of glycogen synthase protein was quantitated by scanning densitometry (Molecular Dynamics, Inc., Sunnyvale, CA) and expressed relative to the amount of total protein.
Analytical measurements
Plasma glucose was determined with an automated glucose oxidase method (Glucose Analyzer 2, Beckman Coulter, Inc., Fullerton, CA). Plasma insulin was measured using a double antibody RIA (Pharmacia Biotech, Uppsala, Sweden) and hemoglobin A 1c (HbA 1c ) was measured by high pressure liquid chromatography (12, 13) .
Statistical analysis
Data are expressed as the mean Ϯ sem. Statistical analysis was performed using an NCSS 6.0.21 statistical package (NCSS Statistical Software, Kaysville, UT). The significance of difference within or between groups was tested by Wilcoxon or Mann-Whitney rank tests. The relationship between various variables was analyzed by Spearman correlations.
Results

Clinical characteristics of the subjects
Fasting plasma glucose and HbA 1c levels were higher in the diabetic and the nondiabetic twins than in the control subjects ( Table 1) . Seven of the nondiabetic twins had impaired glucose tolerance. Plasma insulin concentrations in the basal state and during the clamp were similar in the diabetic (9.7 Ϯ 2.3 and 73.6 Ϯ 7.2 U/mL) and the nondiabetic (7.1 Ϯ 0.9 and 69.4 Ϯ 5.7 U/mL) twins and the control subjects (6.4 Ϯ 0.7 and 78.0 Ϯ 4.5 U/mL). Plasma glucose concentrations in the basal state were only slightly higher in the diabetic twins compared with those in the nondiabetic twins (7.0 Ϯ 0.2 vs. 5.5 Ϯ 0.2 mmol/L; P Ͻ 0.001) and control subjects (7.0 Ϯ 0.2 vs. 5.4 Ϯ 0.2 mmol/L; P Ͻ 0.001). The diabetic twins had 55% lower rates of insulin-stimulated glucose uptake (P Ͻ 0.01), 63% lower rates of glucose storage (P Ͻ 0.01), and 37% lower rates of glucose oxidation (P Ͻ 0.01) compared with the control subjects ( Table 1 ). The nondiabetic monozygotic cotwins also had a 25% lower rate of insulin-stimulated glucose uptake (8.5 Ϯ 0.8 vs. 11.4 Ϯ 0.9 mg/kg fat-free mass⅐min; P Ͻ 0.03), which was due to a 37% decrease in the rate of glucose storage (4.8 Ϯ 0.6 vs. 7.6 Ϯ 0.9 mg/kg fat-free mass ⅐min; P Ͻ 0.02) compared with that in the control subjects (Table 1) .
Glycogen synthase activity
Insulin infusion increased GYS1 fractional activity in all subjects, with no significant difference between the groups. However, when expressed as the increment (⌬FV 0.1) over basal, GYS1 fractional activity was significantly impaired in the diabetic twins compared with the control subjects (P Ͻ 0.01; Fig. 1 ). Of note, ⌬FV 0.1 was not significantly impaired in the nondiabetic twins compared with that in the control subjects (Fig. 1) . The GYS1 ⌬FV 0.1 activity correlated with the rate of insulin-mediated glucose uptake (r ϭ 0.62; P Ͻ 0.001) and glucose storage (r ϭ 0.57; P Ͻ 0.001). There was a weaker correlation between the absolute insulin-stimulated GYS1 FV 0.1 values and rates of glucose uptake (r ϭ 0.39; P ϭ 0.01) and storage (r ϭ 0.34; P ϭ 0.04). Total GYS1 activity after the clamp was not different among the three groups (Table 1) .
GYS1 mRNA expression
Insulin infusion increased GYS1 mRNA expression 12-fold in the control subjects (from 0.14 Ϯ 0.02 to 1.74 Ϯ 0.10 relative units; P Ͻ 0.01) and 8-fold in the nondiabetic twins (from 0.24 Ϯ 0.05 to 1.81 Ϯ 0.16 relative units; P Ͻ 0.01), but only 5-fold (from 0.20 Ϯ 0.07 to 1.08 Ϯ 0.14 relative units; P Ͻ 0.01; Fig. 2 ) in the diabetic twins. Therefore, stimulation of GYS1 mRNA expression by insulin was impaired in the diabetic (P ϭ 0.002), but not in the nondiabetic, cotwins compared with that in the control subjects (Fig. 2) . When the nondiabetic twins were divided into subgroups of normal glucose tolerance (NGT) and impaired glucose tolerance (IGT), both subgroups showed a similar insulin-induced increase in GYS1 mRNA expression [NGT, from 0.28 Ϯ 0.10 to 1.71 Ϯ 0.23 relative units (P Ͻ 0.05; n ϭ 5); IGT, from 0.19 Ϯ 0.01 to 1.95 Ϯ 0.24 relative units (P ϭ 0.06; n ϭ 4)] compared with that in the control subjects. There was no significant correlation between postclamp GYS1 mRNA levels and postclamp GYS1 fractional activity when expressed as either absolute (r ϭ 0.20; P ϭ NS) or incremental (r ϭ 0.29; P ϭ 0.11) values, nor was there any correlation between the postclamp GYS1 mRNA level and the postclamp GYS1 total activity (r ϭ 0.10; P ϭ NS). However, the level of insulin-stimulated GYS1 mRNA expression showed a strong inverse correlation with the HbA 1c concentration (r ϭ Ϫ0.61; P Ͻ 0.001; Fig. 3 ). There was also an inverse correlation between the incremental GYS1 fractional activity and the HbA 1c concentration (r ϭ Ϫ0.46; P Ͻ 0.01).
GYS1 protein
The postclamp GYS1 protein levels did not significantly differ between the diabetic twins and the control subjects (2.10 Ϯ 0.46 and 2.10 Ϯ 0.34 relative units; P ϭ NS; Fig. 4 ). In the control subjects, the postclamp GYS1 protein concentrations correlated strongly with the total GYS1 activity (r ϭ   FIG. 1 . Insulin-stimulated GYS1 activity in skeletal muscle of diabetic (n ϭ 12) and nondiabetic (n ϭ 12) twins and control subjects (n ϭ 12). Muscle biopsies were taken from the vastus lateralis muscle in the basal state and after a 3-h euglycemic insulin clamp (40 mU/ m Ϫ2 ⅐min Ϫ1 ). GYS1 activities were measured at a physiological glucose-6-phosphate concentration (0.1 mmol/L) and in the presence of a maximal stimulatory glucose-6-phosphate concentration (10 mmol/L). ⌬FV values are insulinstimulated increments in fractional velocities over the basal values. ⌬FV 0.1 was significantly lower in the diabetic twins compared with that in the control subjects (15.7 Ϯ 3.3% vs. 23.7 Ϯ 1.8%; P Ͻ 0.01). B, baseline; C, clamp. 2 . The stimulatory effect of insulin on GYS1 mRNA expression in skeletal muscle of diabetic (n ϭ 11) and nondiabetic (n ϭ 9) twins and control subjects (n ϭ 10). Total RNA was extracted from muscle biopsies taken before and after a 3-h euglycemic insulin clamp. GYS1 gene expression was measured by relative RT-PCR and expressed relative to cyclophilin. Insulin increased GYS1 mRNA levels in all groups (P Ͻ 0.01), but postclamp GYS1 mRNA levels were significantly lower in the diabetic twins compared with the control subjects (P Ͻ 0.003). The increase in GYS1 mRNA levels over basal values was significantly lower in the diabetic twins compared with the control subjects (P ϭ 0.001). B, Baseline; C, clamp.
0.72; P ϭ 0.03; n ϭ 9), but not with the fractional GYS1 activity (r ϭ 0.22; P ϭ NS). No such correlation was seen in the diabetic twins, nor was there any significant correlation between postclamp GYS1 protein and mRNA concentrations (r ϭ 0.29; P ϭ NS).
Discussion
By studying monozygotic twins discordant for diabetes we were able to distinguish between inherited and acquired defects in insulin-stimulated glycogen synthase activity and gene expression in human skeletal muscle. Impaired stimulation of GYS1 activity and mRNA expression by insulin is most likely an acquired defect secondary to hyperglycemia, as 1) it was not seen in the nondiabetic cotwins; and 2) it showed a strong inverse correlation with the HbA 1c concentration. The observation that GYS1 activity and mRNA levels were not completely normal in the nondiabetic cotwins is most likely due to the fact that seven of them had IGT and were thus exposed to slightly higher levels of glucose than the control subjects. The study also reinforced the previously demonstrated disparity between GYS1 mRNA and protein levels (10, 21) . From these data it is tempting to speculate that the amount of GYS1 protein has little bearing on the development of impaired GYS1 activity, because it is always present in sufficient amounts. Impaired GYS1 fractional activity in the diabetic twins may therefore not be explained by its defective gene expression but, rather, by posttranslational defects, i.e. defects in GYS1 enzyme kinetic properties. In keeping with this view, we found that GYS1 protein levels correlated with its total activity only in the control, not in diabetic, subjects. As the total activity of GYS1 was measured at saturating levels of the substrate (UDPG) and the allosteric activator (glucose-6-phosphate), the total activity can be considered as an index of the total amount of GYS1 protein (22) .
The lack of correlation between these two variables in the diabetic twins point at abnormalities at the regulatory site of the enzyme.
The lack of correlation between GYS1 mRNA and fractional activity is more difficult to explain. Insulin increases GYS1 activity through dephosphorylation and allosteric modification by glucose-6-phosphate. Insulin also regulates expression of a number of genes involved in glucose metabolism and insulin action, such as phosphoenolpyruvate carboxykinase, Rad, the p85␣ subunit of PI3-kinase, Glut4, HKII (23) (24) (25) (26) , and the mitochondria-encoded oxidative phosphorylation genes (20) . However, insulin regulation of GYS1 gene expression is poorly known. In partial contrast to our findings, longer clamping for 4 h had no significant effect on GYS1 mRNA (21, 27) and protein levels (10, 21, 27) in either control or diabetic subjects. Despite this, in the control subjects in these studies, GYS1 mRNA expression relative to total RNA tended to increase after insulin infusion (21, 27) . Although differences in study subjects and/or experimental methods, e.g. the age of studies, the internal RNA reference, etc., could provide potential explanations for this variation, the possible time course of the insulin effect should also be considered. In support of this, GYS1 mRNA levels increased after 1 h of exposure of cultured human skeletal muscle cells to 33 nmol/L insulin without significant changes in GYS1 mRNA and its protein expression after 4 days of exposure (11) . Similarly, Okubo et al. showed an initial increase in glycogen synthase mRNA expression 1 h after exposure of hepatoma H4 cells to insulin, with a subsequent decline (28) . In keeping with these findings we observed a temporary increase in glycogen synthase gene expression in skeletal muscle from rats exposed to 36 h of insulin infusion (unpublished data). In the present study we observed a significant increase in GYS1 mRNA expression not only in the   FIG. 4 . GYS1 protein content in skeletal muscle of the diabetic twins (n ϭ 10) and the control subjects (n ϭ 9) after a 3-h insulin clamp.
control subjects but also in the diabetic subjects after 3 h of insulin infusion. The precise nature by which insulin influences GYS1 gene expression is not known. We did not find any core sequences of the known insulin response elements (IREs) in a promoter region 1.7 kb upstream of the translation start site of the GYS1 gene (29) by searching sequence similarity with the known IREs (30) . This could suggest that the putative IRE might be located further upstream of the promoter of the GYS1 gene.
Fractional and total GYS1 activities as well as mRNA levels were similar in the basal state among type 2 diabetic twins, nondiabetic twins, and control subjects. This is in contrast to some previous studies reporting decreased basal (fasting) fractional and total GYS1 activities (9, 22) or GYS1 mRNA expression (9, 10) in type 2 diabetic subjects compared with control subjects. One explanation for this discrepancy could be that we used a prior iv insulin infusion to lower the compensatory effect of fasting hyperglycemia on glucose metabolism. Thereby we obtained similar basal plasma insulin concentrations and nearly similar basal plasma glucose concentrations in the diabetic and nondiabetic twins and the control subjects. Thus, the basal or preclamp measurements of GYS1 enzyme activity, mRNA, and protein levels in the diabetic twins in this study were more comparable to those in the nondiabetic controls compared with studies in which the basal muscle biopsies in diabetic subjects were taken at higher fasting plasma glucose and insulin levels. In this scenario, the lower GYS1 ⌬FV 0.1 activity in the diabetic twins would represent the impaired response to insulin stimulation.
The data, however, clearly showed that expression of the GYS1 mRNA is resistant to the action of insulin in patients with type 2 diabetes and that this insulin resistance obviously is an acquired defect due to chronic hyperglycemia. High glucose has been shown to influence the expression of a number of genes, including the insulin gene in pancreatic ␤-cells, by interfering with glucose response elements (31) . Nothing is known about the putative mechanisms by which high glucose could influence GYS1 gene expression. GYS1 mRNA expression was decreased in skeletal muscle in the insulin-resistant type 2 diabetic patients (9, 10), but not in insulin-resistant nondiabetic subjects (32) . The decreased GYS1 mRNA expression was also observed in skeletal muscle cultures from type 2 diabetic patients and was restored to normal by insulin infusion (33) . Thus, this may suggest a role for glucose toxicity in down-regulation of the GYS1 mRNA expression in diabetic patients, as indicated by the inverse correlation between GYS1 mRNA expression and HbA 1c shown in the present study. A decrease in GYS1 protein concentration would be expected to follow its decreased mRNA expression. The disparity between GYS1 mRNA and its protein expression in the diabetic patients points at the presence of compensatory mechanisms at the posttranscriptional level. In keeping with this view, it has been shown in man that acute physiological elevation of circulating insulin levels inhibits protein breakdown (34) . Other studies have shown that insulin treatment restores overall protein synthesis in diabetic animals (35) and increases protein synthesis of glycogen synthase in rat hepatoma H4 cells (36) . The similarity of GYS1 protein concentrations between diabetic and control subjects would imply that this effect is normally sensitive to insulin in diabetic subjects.
In summary, insulin up-regulates skeletal muscle glycogen synthase mRNA expression, and this effect is impaired in type 2 diabetes. This defect is acquired and most likely secondary to chronic hyperglycemia.
